Greenyn Biotechnology Awarded the 'Potential Benchmark Award' at the 2021 Taiwan BIO Awards

Greenyn Biotechnology Receives the 'Potential Benchmark Award' at the 2021 Taiwan BIO Awards. On November 4th, at the physical exhibition of 'BIO Asia-Taiwan 2021', the award was presented by former Vice President Academician Chen Chien-jen, recognizing Greenyn Biotechnology for its research and development capabilities, future potential, and significant contributions to the advancement of the biotechnology industry and economic development in Taiwan.

Greenyn Biotechnology is dedicated to innovation and improving public health. Our goal is to lead Taiwan's biotechnology health industry globally. We develop unique health food ingredients in Taiwan, ensuring their effectiveness through rigorous science and clinical testing.

In recent achievements, "Antromax® Antrodia Cinnamomea Mycelia " received FDA approval as the first A. cinnamomea product for import to the U.S. "Insumate® ® Patented Amino Peptide Sequence mcIRBP-19" has gained international patents and three major global invention awards, backed by two clinical validations, making it the only bitter melon extract with such recognition. Furthermore, our Zymologist® 101 Phyto Fermented Drink, derived from 101 fresh fruits and vegetables, meets high SOD-like activity and low sugar content while aiding in regulating physiological functions without excess sugar intake.

With over 25 years of experience, Greenyn Group integrates in-house R&D, international sourcing, and ODM design to boost clients' product competitiveness. Supported by nutritionists, we offer one-stop services from research to sales, swiftly introducing high-quality Taiwanese products to the market.